Marrone Bio Innovations Inc (MBII) Formed a Bearish Double Bottom Pattern, Could Be One of The Worst Performers Going Forward

September 17, 2017 - By Clifton Ray

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.29, from 1.29 in 2016Q3. It is negative, as 3 investors sold Marrone Bio Innovations Inc shares while 3 reduced holdings. 3 funds opened positions while 3 raised stakes. 9.11 million shares or 2.31% less from 9.33 million shares in 2016Q3 were reported.
Northern Trust reported 22,275 shares stake. Waddell & Reed has 0.02% invested in Marrone Bio Innovations Inc (NASDAQ:MBII). Geode Capital Mngmt Limited Liability Corporation owns 74,484 shares. Primecap Mgmt Company Ca has 0.01% invested in Marrone Bio Innovations Inc (NASDAQ:MBII). Bridgeway Cap Mgmt Inc stated it has 181,200 shares or 0.01% of all its holdings. Ardsley Advisory Ptnrs has invested 0.27% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Vanguard Grp has 339,993 shares. Wells Fargo Mn holds 200 shares or 0% of its portfolio. State Street reported 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Spark Invest Mgmt Ltd Liability Corp has invested 0.01% in Marrone Bio Innovations Inc (NASDAQ:MBII). Morgan Stanley holds 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII) for 480 shares. Hanson Mcclain stated it has 10,000 shares or 0% of all its holdings. Architects Inc holds 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII) for 3,485 shares. Ogorek Anthony Joseph Adv holds 300 shares or 0% of its portfolio. Savant Capital Ltd Liability Company has invested 0.01% in Marrone Bio Innovations Inc (NASDAQ:MBII).

The chart of Marrone Bio Innovations Inc (MBII) shows a double bottom with $1.01 target or 9.00 % below today’s $1.11 share price. The 8 months chart pattern indicates high risk for the $34.80 million company. It was reported on Sep, 17 by Finviz.com. If the $1.01 price target is reached, the company will be worth $3.13 million less. Double bottoms are rare but powerful chart patterns.

The stock decreased 0.89% or $0.01 on September 15, reaching $1.11. About 94,665 shares traded. Marrone Bio Innovations Inc (NASDAQ:MBII) has risen 94.03% since September 17, 2016 and is uptrending. It has outperformed by 77.33% the S&P500.

Analysts await Marrone Bio Innovations Inc (NASDAQ:MBII) to report earnings on November, 13. They expect $-0.24 earnings per share, up 17.24 % or $0.05 from last year’s $-0.29 per share. After $-0.25 actual earnings per share reported by Marrone Bio Innovations Inc for the previous quarter, Wall Street now forecasts -4.00 % EPS growth.

Marrone Bio Innovations Inc (NASDAQ:MBII) Ratings Coverage

Among 3 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Marrone Bio Innovations had 5 analyst reports since August 11, 2015 according to SRatingsIntel. Piper Jaffray maintained Marrone Bio Innovations Inc (NASDAQ:MBII) rating on Monday, August 14. Piper Jaffray has “Hold” rating and $2.0 target. The firm has “Buy” rating by Zacks given on Tuesday, August 11. The firm earned “Buy” rating on Wednesday, March 16 by Rodman & Renshaw. The rating was maintained by H.C. Wainwright on Tuesday, August 15 with “Buy”. The stock of Marrone Bio Innovations Inc (NASDAQ:MBII) has “Hold” rating given on Friday, July 21 by Piper Jaffray.

More notable recent Marrone Bio Innovations Inc (NASDAQ:MBII) news were published by: Globenewswire.com which released: “California Cannabis Growers Now Have Access to Safe and Effective …” on June 12, 2017, also Globenewswire.com with their article: “Marrone Bio Innovations, Inc. Products Show Impressive Results in …” published on July 10, 2017, Seekingalpha.com published: “Short Squeeze Coming In Marrone Bio Innovations?” on August 28, 2017. More interesting news about Marrone Bio Innovations Inc (NASDAQ:MBII) were released by: Bizjournals.com and their article: “Davis-based Marrone Bio Innovations partners with app developer for pilot program” published on September 14, 2017 as well as Nasdaq.com‘s news article titled: “Marrone Bio Innovations, Inc. Reports Second Quarter 2017 Financial Results” with publication date: August 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.